The stock of Medpace Holdings Inc (NASDAQ:MEDP) hit a new 52-week high and has $40.10 target or 9.00% above today’s $36.79 share price. The 9 months bullish chart indicates low risk for the $1.52B company. The 1-year high was reported on Nov, 28 by Barchart.com. If the $40.10 price target is reached, the company will be worth $136.80 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 68,112 shares traded hands. Medpace Holdings Inc (NASDAQ:MEDP) has risen 6.00% since October 29, 2016 and is uptrending. It has underperformed by 0.01% the S&P500.
Analysts await Medpace Holdings Inc (NASDAQ:MEDP) to report earnings on February, 2. MEDP’s profit will be $14.05M for 27.05 P/E if the $0.34 EPS becomes a reality. After $0.35 actual EPS reported by Medpace Holdings Inc for the previous quarter, Wall Street now forecasts -2.86% negative EPS growth.
Medpace Holdings Inc (NASDAQ:MEDP) Ratings Coverage
Out of 5 analysts covering Medpace Holdings Inc. – Common Stock (NASDAQ:MEDP), 3 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 60% are positive. Medpace Holdings Inc. – Common Stock has been the topic of 5 analyst reports since September 6, 2016 according to StockzIntelligence Inc. The rating was initiated by Credit Suisse with “Outperform” on Tuesday, September 6. UBS initiated it with “Buy” rating and $35 target price in Tuesday, September 6 report. The stock of Medpace Holdings Inc (NASDAQ:MEDP) has “Neutral” rating given on Tuesday, September 6 by Robert W. Baird. As per Tuesday, September 6, the company rating was initiated by Jefferies. The rating was initiated by Wells Fargo on Tuesday, September 6 with “Outperform”.
According to Zacks Investment Research, “Medpace Holdings, Inc. is a scientifically-driven, global, full-service clinical contract research organization which provides Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace Holdings, Inc. is headquartered in Cincinnati, Ohio.”
More notable recent Medpace Holdings Inc (NASDAQ:MEDP) news were published by: Businesswire.com which released: “Medpace Holdings, Inc. Reports Third Quarter 2016 Results” on November 03, 2016, also Businesswire.com with their article: “Medpace Holdings, Inc. Announces Pricing of Initial Public Offering” published on August 10, 2016, Businesswire.com published: “Medpace Holdings, Inc. to Report Third Quarter 2016 Financial Results on …” on October 17, 2016. More interesting news about Medpace Holdings Inc (NASDAQ:MEDP) were released by: Moodys.com and their article: “Moody’s upgrades Medpace to B1; outlook stable” published on August 25, 2016 as well as Marketwired.com‘s news article titled: “Medpace Holdings, Inc. Files Registration Statement for Proposed Initial …” with publication date: June 24, 2016.
MEDP Company Profile
Medpace Holdings, Inc. is a holding company. The Firm operates as a clinical contract research organization (CRO) focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Firm is focused on conducting clinical trials across therapeutic areas, with focus in cardiology, metabolic disease, oncology, endocrinology, central nervous system (CNS), and Anti-Viral and Anti-Infective (AVAI). The Firm provides a suite of services supporting the entire clinical development process from Phase I to Phase IV. It offers these services across a range of therapeutic areas. The Company’s suite of clinical development services includes Medical Affairs, Clinical Trial Management, Study Feasibility, Study Start-Up, Clinical Monitoring, Global Regulatory Affairs, Medical Writing, Biometrics, Pharmacovigilance, Core Laboratory, Quality Assurance, Laboratories, Clinics and Customers.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.